market access

News

Novartis' Basel HQ: the company is looking for more blockbusters to lift revenues

Novartis posts modest growth as Narasimhan takes charge

Swiss pharma giant Novartis saw modest growth of 2% in 2017, with growth in Cosentyx and Entresto offsetting generic erosion to its cancer blockbuster Gleevec/Glivec.

News

NICE must be reformed - Janssen UK market access chief

Janssen’s UK pricing chief Jennifer Lee has called for reform of NICE following the company’s successful but drawn-out attempt to get its cancer drug Darzalex to NHS patients.

News

Roche's MS drug Ocrevus priced in line with Novartis rival i...

Drug likely to cost just under £10,000 per six-monthly injection.

News

NICE backs interim funding for Janssen cancer drug

NICE has recommended that Janssen’s Darzalex (daratumumab) should be reimbursed on an interim basis by the Cancer Drugs Fund in pre-treated multiple myeloma, after months of wrangling.

News

Dengue, zika and chikungunya fever mosquito (aedes aegypti) on human skin

Sanofi to pay back Philippines after Dengue vaccine problems

Sanofi’s is to pay back money to the Philippines government for unused doses of its Dengue fever vaccine, after serious safety concerns halted its use.

News